Mode
Text Size
Log in / Sign up
N/A N=17 Treatment

Effects of a Very Low Carbohydrate Diet on Symptoms of Irritable Bowel Syndrome (IBS)

Diarrhea Predominant Irritable Bowel Syndrome

Enrolled (actual)
17
Serious AEs
0.0%
Results posted
Nov 2011
Primary outcome: Primary: Number of Subjects Reporting "Adequate Relief" From IBS Symptoms for the Previous Week. Adequate Relief Was a "True/False" Item. — 13 Participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Very low carbohydrate diet (Other)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
University of North Carolina, Chapel Hill
Primary completion
May 2010

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Subjects Reporting "Adequate Relief" From IBS Symptoms for the Previous Week. Adequate Relief Was a "True/False" Item.
13
SECONDARY
Impact of Very Low Carbohydrate Diet on Stool Frequency
2.6
SECONDARY
Sickness Impact Profile
2.3 .001 sig

Summary

The purposes of this study are to prospectively determine the effect of a very low carbohydrate diet on quality of life and gastrointestinal symptoms in patients with diarrhea-predominant irritable bowel syndrome (IBS-D); and to determine possible physiological correlates of symptom improvement, as related to post-prandial 5-hydroxytryptamine (5-HT) release, weight loss and fiber content.

Eligibility Criteria

Inclusion Criteria

  • Age 18-70 years old, male or female
  • Meet Rome II Criteria for IBS-D
  • Body mass index > 25 kg/m^2
  • Desire to use a very low carbohydrate diet for weight loss
  • Score of > 36 on the FBDSI
  • Ability to understand consent form
  • In stable health by screening history, physical examination performed by a study physician, laboratory tests (normal blood counts, kidney function tests, liver tests, TSH).

Exclusion Criteria

  • Age 70 years
  • History of inflammatory bowel disease
  • History of any gastrointestinal surgery that preceded the onset of IBS symptoms
  • Pregnancy or breastfeeding
  • FBDSI symptom score of ≤ 36
  • Inability to understand consent form
  • Diabetes requiring medications (must be controlled with diet and exercise alone).
  • Chronic narcotic use for any reason
  • Use of serotonin-selective reuptake inhibitors unless patient has been on a stable dose for at least 4 weeks.
  • Use of any over-the-counter or prescription weight loss medications.
  • Any chronic or unstable diseases (e.g., kidney disease, heart disease, or cancer) that may put the subject at increased risk from the intervention
  • Any of the following baseline abnormalities of laboratory tests or physical exam findings:
  • Serum creatinine > 1.5 mg/dL in men, > 1.3 mg/dL in women.
  • Liver disease (AST or ALT > 2 times the upper limit of normal or total bilirubin > 1.6mg/dL).
  • Blood pressure > 160/100 mm Hg.
  • Fasting triglycerides > 600 mg/dL.
  • Fasting serum low-density lipoprotein (LDL) cholesterol > 190 mg/dL.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00616200). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search